Drug Trial Radar · NCT05653856
Cu-64-PSMA-I&T Positron Emission Tomography (PET) Imaging of Metastatic PSMA Positive Lesions in Men With Prostate Cancer
Last checked: Nov 20, 2026Latest source record: Jan 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
26
Actual
Start
Dec 5, 2022
Primary completion
May 17, 2023
Study completion May 17, 2023
Sponsor
- Lead sponsor
- Curium US LLCIndustry
- Sponsor type
- Industry
- First posted
- Dec 16, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, open-label Phase 2 study to evaluate copper Cu 64 PSMA I\&T injection for PET/CT imaging in patients with recurrent metastatic prostate cancer after radical prostatectomy or radiation therapy.
Conditions
- Metastasis From Malignant Tumor of Prostate (Disorder)
Interventions
64Cu-PSMA I&TDrug
Radiolabeled Receptor-Targeted Diagnostic Product
Primary outcomes
What the sponsor says the trial is designed to measure.
- Region-Level Correct Localization Rate (CLR)Time frame: 4 Hours
- Patient-Level Correct Detection Rate (CDR)Time frame: 4 Hours
- Incidence of Adverse EventsTime frame: 24 Hours
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Yale University
New Haven, Connecticut
Edward Hines, Jr. VA Hospital
Hines, Illinois
Johns Hopkins University
Baltimore, Maryland
Saint Louis University
St Louis, Missouri
John J. Cochran Veterans Hospital
St Louis, Missouri
Washington University
St Louis, Missouri
Nebraska Cancer Specialists
Omaha, Nebraska
XCancer Omaha/Urology Cancer Center
Omaha, Nebraska
MD Anderson
Houston, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.